| Literature DB >> 26959063 |
N Rajendra Prasad1, Ganesan Muthusamy2, Mohana Shanmugam3, Suresh V Ambudkar4.
Abstract
Cancer is a hyperproliferative disorder that involves transformation, dysregulation of apoptosis, proliferation, invasion, angiogenesis and metastasis. During the last 30 years, extensive research has revealed much about the biology of cancer. Chemotherapy and radiotherapy are the mainstays of cancer treatment, particularly for patients who do not respond to surgical resection. However, cancer treatment with drugs or radiation is seriously limited by chemoresistance and radioresistance. Various approaches and strategies are employed to overcome resistance to chemotherapy and radiation treatment. Many plant-derived phytochemicals have been investigated for their chemo- and radio-sensitizing properties. The peoples of South Asian countries such as India, Pakistan, Sri Lanka, Nepal, Bangladesh and Bhutan have a large number of medicinal plants from which they produce various pharmacologically potent secondary metabolites. The medicinal properties of these compounds have been extensively investigated and many of them have been found to sensitize cancer cells to chemo- and radio-therapy. This review focuses on the role of South Asian medicinal compounds in chemo- and radio-sensitizing properties in drug- and radio-resistant cancer cells. Also discussed is the role of South Asian medicinal plants in protecting normal cells from radiation, which may be useful during radiotherapy of tumors to spare surrounding normal cells.Entities:
Keywords: ABC transporter; South Asian plants; chemoresistance; phytochemicals; radioresistance
Year: 2016 PMID: 26959063 PMCID: PMC4810116 DOI: 10.3390/cancers8030032
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Bioactive compounds from selected South Asian medicinal plants.
| Name of the Plant | Bioactive Compounds |
|---|---|
| WithaferinA, withanolide | |
| Nirtetralin, niranthrin, phyllanthin, phyltetralin | |
| Embilins | |
| Annomuricins, bullatacin | |
| (−)-Wikstromal, (−)-matairesinoland dibenzylbutyrolactol | |
| Camptothecin, irinotecan | |
| Boswellic acid, acetyl-β-boswellic acid, α-pinene | |
| Andrographolide, betulin, betulinic acid | |
| Asiaticoside, hydrocotyline, vallerine, pectic acid, stigmasterol, thankunosides and ascorbic acid | |
| Berberine, palmatine, 8-oxoprotoberberine, oxypalmatine, berberrubine | |
| Amooranin, rohitukine | |
| Glycophosphosphingolipids | |
| Diterpenoids and pimaren | |
| Cuscutin, amarbelin, β-sterol, stigmasterol, kaempferol, dulcitol, myricetin, quercetin, coumarin and oleanolic acid | |
| Quercetrin, catechin, gallic acid, chebulinic acid, oleonolic acid, β-amyrin-O-acetate, leucocynidin, β-sitosterol and stigmasterol | |
| Kaempferol- 3,5-dimethyl ether, caryatin, (L)-catechin, myricetin, quercetin-3-O galactopyranoside, myricetin-3-O-galactopyranoside, diosbulbin B | |
| Quercitol, diethylnitrosamine/Phenobarbital | |
| Lupeol, psoralen and β-sisterol | |
| Quercetin and qyricetin, stigmasterol and β-sitosterol | |
| Stigmasterol β-sitosterol, quercetin, kaempferol | |
| Falodone and jatrophone | |
| Agnucastoside A, agnucastoside B and agnucastoside C, aucubin, agnuside, mussaenosidic acid | |
| Apigenin and mollupentin, mmollugogenol A, mollugogenol B, mollugogenol D, oleanolic acid and β-sitosterol | |
| Liensinine, neferine, pronuciferine, isoliensinine, negferine, asimilobine, nuciferine, remrefidine, isoliensinine, myricetin, quercetin, leucocyanidin, kaempferol, astragalin | |
| Phenylpropanoid glycosides, carotenoid glucosides, phenyl-propanoid glycoside cardiac glycosides, polysaccharides, β-sitosterol, β-amyrin, hentriacontane benzoic acid, nyctanthic acid, friedelin, lupeol, oleanolic acid, 6β-hydroxylonganin alkaloids, phlobatanins, terpenoids | |
| 4-Hydroxybenzoic acid, caffeic acid, rutin, ferulic acid, coumaric acid, epigallocatechin gallate, quercetin, myricetin, and kaempferol | |
| Gentisic acid, luteolin, apigenin, kaempferol, m-coumaric acid, anthocyanidin, lunasin | |
| Brucine, diaboline | |
| Gingerenonea, gingeols, shogaols, zingerone | |
| Coumarins xanthyletin, xanthoxyletin and 7-demethylsuberosin | |
| Podophyllin, astragalin | |
| Cynogenetic glycosides | |
| Glycyrrhizin | |
| Vinblastine, vincristine, alstonine, ajmalicine and reserpine | |
| Epigallocatechin gallate | |
| Aloe-emodin, emodin, aloin acemannan | |
| Alliin, allicin alliin, alliinase, S-allylcysteine, diallyldisulphide, diallyltrisulphide and methylallyltrisuphide. | |
| Curcumin | |
| Capsaicin | |
| Piperidine, piperine |
Mechanisms by which tumor cells resist radiation and chemotherapeutic drugs.
| Radioresistance | Chemoresistance |
|---|---|
| Tumor hypoxic condition | Increased drug efflux and decreased drug uptake |
| Increased cellular production of cellular antioxidants | Inactivation of apoptosis |
| Activation of certain proto-oncogenes, and stromal interactions | Increased drug metabolism and drug compartmentalization |
| Amplification of DNA repair genes | Increase in the repair of DNA damage |
| Cancer stem cells as contributors to radioresistance | Increased or altered the drug targets |
| Survival signals favoured by transcription factors | Survival signals favoured by transcription factors |
Figure 1Chemical structure of selected active compounds derived from South Asian Medicinal Plants.
Figure 2Selected targets of South Asian phytochemicals linked to chemosensitization. The indicated compounds in colored boxes interact with cell surface ABC transporters such as P-gp, ABCG2, and receptor tyrosine kinases including TRIAL-R, FLT3, KIT, VEGFR and EGFR. Some of the medicinal compounds also interact with intracellular tyrosine kinases (BCR-ABL kinase). The dashed lines indicate that the phytochemicals inhibit ABC drug transporters such as P-gp and ABCG2 resulting in chemosensitization. The solid lines depict inhibition of targets such as KIT and FLT3 resulting in chemosensitization.
Chemosensitizing potential of selected South Asian medicinal compounds.
| Natural Products | Anticancer Drugs | Experimental Models | Mechanism of Action | Ref. |
|---|---|---|---|---|
| Morin | Doxorubicin | MCF-7 MDA435/LCC6 cells | Inhibit P-gp-mediated drug efflux and potentiate doxorubicin cytotoxicity in P-gp positive cells. | [ |
| Vincristine | K562 and K562/ADM | Pentaethylmorin remarkably increased the drug uptake in MDR cells. | [ | |
| Daunorubicin | Multidrug resistant human breast cancer cell lines | Increased [3H]daunorubicin accumulation in MDR breast cell lines. | [ | |
| Doxorubicin | MCF-7 and MDA435/L | Potentiates doxorubicin cytotoxicity in MDA435/L cells. | [ | |
| Biochanin A | Doxorubicin | MCF-7 MDA435/LCC6 cells | Biochanin A can potentiate doxorubicin cytotoxicity in Pgp positive cells | [ |
| Quercetin | Vincristine | K562 and K562/ADM | Pentamethyl quercetin and pentaallylquercetin remarkably increase drug uptake | [ |
| Vincristine | MBEC4 cells and ddY mice | Increased drug uptake in cells and enhanced brain-to-plasma concentration ratio in mice | [ | |
| Doxorubicin | Cultured rat hepatocytes | Reduced drug retention with increase in its efflux | [ | |
| Tamoxifen | Female SD rats | AUC, Ka, Cmax increased | [ | |
| Paclitaxel | Male SD rats | AUC, Ka, Cmax increased | [ | |
| Vinblastine and paclitaxel | MDR KB-V1 cells | Reduced P-gp expression and function. | [ | |
| Phloretin | Doxorubicin | MCF-7 MDA435/LCC6 cells | Inhibit P-gp-mediated drug efflux; phloretin can potentiate doxorubicin cytotoxicity in P-gp positive cells. | [ |
| Nobiletin | Vincristine | K562/ADM | Increased drug uptake in K562/ADM cells. | [ |
| Chrysin | Vincristine | MBEC4 cells and ddY mice | Increased drug uptake in cells and enhanced brain-to-plasma concentration ratio in mice | [ |
| Kaempferol | Doxorubicin | Cultured rat hepatocytes | Kaempferol potentiated the toxic effect of chemotherapeutic agent and decreasing the efflux of doxorubicin | [ |
| (–)-Epigallocatechin gallate (EGCG) | Doxorubicin | P-gp over-expressing KB-C2 cells | Increased drug accumulation | [ |
| Green tea polyphenols | Vinblastine | Multidrug-resistant cell line CH(R)C5 | Potentiates the vinblastine cytotoxicity in CH(R)C5 cells. | [ |
| Genistein | Rhodamine 123 and daunorubicin | P-gp-expressing cells | Elevation in intracellular drug accumulation | [ |
| Kaempferol | Vinblastine and paclitaxel | MDR KB-V1 cells | Reduced P-gp expression and function | [ |
| Tamoxifen | male rats | AUC, Ka, Cmax increased | [ | |
| Heptamethoxyflavone | vincristine | K562/ADM | Increased uptake of [3H] vincristine | |
| Phloretin, silymarin | Daunorubicin& doxorubicin | Multidrug resistant human breast cancer cell lines MCF- 7 and MDA435/L | Increased [3 H]Daunomycin accumulation & potentiated doxorubicin Cytotoxicity | [ |
| EGCG | Paclitaxel | Breast cancer cells (4T1, MCF-7, and MDA-MB- 231) Female Balb/c mice (4T1) cells xenograft) and various carcinoma cells | Induces apoptosis and increased endoplasmic reticulum chaperone GRP78 expression in tumor tissues. Decreases PCNA immunostaining | [ |
| Curcumin | Carboplatin | NSCLC cell line, A549 | Suppression of NF-κB via inhibition of the Akt/IKKα pathway and enhanced ERK1/2 activity | [ |
| Paclitaxel | Cervical cancer cells | Down-regulation of paclitaxel-induced activation of NF-κB, Akt, and Bcl-2 | [ | |
| Vincristine/ vinblastine | Multidrug resistant KB cells, human multiple myeloma cells | Down-regulated NF-κB or P-gp | [ | |
| EGCG + Curcumin | Cisplatin | Ovarian cancer, A2780, A2780cisR and A2780ZD0473R cells | Lower concentrations and shorter time gap between the two treatments produces higher cytotoxic effects | [ |
| Resveratrol | 5-FU | Chemoresistant cholangiocarcinoma tumor model and B16 murine melanoma cells | Down-regulates Cyp1b1 expression and suppresses cell growth and angiogenesis | [ |
| Paclitaxel | nonHodgkin’s lymphoma and multiple myeloma cell lines, KBv200 | Down-regulation of Bcl-2 family members and MDR1/P-gp. Down-regulation of Bcl-2 family members and MDR1/P-gp. | [ | |
| Doxorubicin or vincristine | human uterine cancer cells , doxorubicin-resistant acute myeloid leukemia cells | Down-regulation of MDR1/P-gp and Bcl-2 | [ | |
| Caffeic Acid Phenylethyl Ester | Vincristine and Doxorubicine | PL104 cells | CAPE an enhancement of cell death | [ |
| Green tea | Doxorubicin | M5076 sarcoma | Increase in accumulation of the antitumor agent | [ |
| Withaferin A and Siamois | Doxorubicin | K562 and K562/Adr cells | Transcriptional inhibition of NF-κB-, AP1- and Nrf2- and overcome the P-gp-coupled attenuation of caspase-dependent apoptosis in K562/Adr cells | [ |
| Piperine | Cyclosproine A | Human colon carcinoma cell line (Caco-2) | Piperine might affect disposition of drugs that are substrates for both P-glycoprotein and CYP3A4 | [ |
| Capsaicin | 5-flourouracil | Gastric cancer cell line HGC-27 | Capsaicin has the potential to treat gastric carcinoma with 5-FU | [ |
| Diallyltrisulfide | Doxorubicin | K562/A02 cells | Increased expression of Caspase-3 and down-regulation of NF-κB/p65, increasing intracellular adriamycin concentration and inducing apoptosis | [ |
| Diallylsulfide | Vinblastine | K562 cells | Enhanced cytotoxic activity of vinblastine as well as other Vinca alkaloids | [ |
| Emodin | Paclitaxel | MDA-MB-361, MDA-MB-453, BT-483, SKBr-3, and BT-474 cells | Sensitizes HER-2/neu-overexpressing breast cancer cells | [ |
| Glycyrrhetinic acid | Daunorubicin | Human carcinoma KB-C2 cells and human MRP1 gene-transfected KB/MRP cells | Dual inhibitory effects on P-glycoprotein and MRP1 | [ |
| (-)-Hydnocarpin | Vincristine | Acute lymphoblastic leukemia cell line | Hydnocarpin potentiating the effect of vincristine in a multidrug-resistant cell line | [ |
| Hesperidin | Doxorubicin | MCF-7 cell line, doxorubicin resistant (MCF-7/Dox) cells | Co-chemotherapy application of doxorubicin and hesperidin on MCF-7/Dox cells showed synergism effect through inhibition of Pgp expression. | [ |
Figure 3Selected targets of South Asian phytochemicals linked to radiosensitization. Exposure to ionizing radiation leads to activation of several transcription factors, expression of numerous cytokines, adhesion molecules, prostaglandins and enzymes that promote radioresistance. The upward black arrows depict up-regulation of indicated transcription factors. Solid lines indicate South Asian medicinal compounds inhibiting transcription potential of pro-inflammatory transcription factors. The curved green arrows indicate downregulation of expression of proinflammatory cytokines and enzymes involved in radioresistance by South Asian medicinal compounds. Dotted lines indicate South Asian medicinal compounds involved in the inhibition of prosurvival, cell proliferation, growth, invasion, angiogenesis and metastasis through various mechanisms.
South Asian medicinal compounds protect normal cells from radiation effects and sensitize cancer cells to radiation effects. South Asian medicinal compounds at the concentration studied protects the normal human cells and experimental animals against indicated radiation dose and sensitizes radiation effects in the cancer cells through different mechanism.
| Name of the Hytochemicals | Concentration Studied | Radiation Dose | Radioprotective/Radiosensitizing Effect | References |
|---|---|---|---|---|
| Curcumin | 50 µg/mL | 1.5 Gy | Curcumin-encapsulated bioglass-chitosan might have promising potential applications for wound healing resulting from gamma radiation. | [ |
| Sesamol | 10 μg/mL | 4 Gy | (i) Renders protection on γ-radiation induced DNA damage, and antioxidants depletion in cultured human lymphocytes. | [ |
| 100 mg/kg | 7.5 Gy | (ii) Acts as a single prophylactic dose protects hematopoietic and GI systems against γ-radiation-induced injury in mice. | ||
| Ferulic acid | 10 μg/mL | 4 Gy | Prevents γ-radiation-induced micronuclei and dicentric aberration in human lymphocytes. | [ |
| 50 mg/kg | 4 Gy | Enhances the survival of mice possibly by decreasing DNA damage as examined by γH2AX foci, micronuclei formation, and comet assay. | ||
| Apigenin | 10 μg/mL | 3 Gy | Significantly reduced ( | [ |
| Mangiferin | 5–25 μg/mL | 5 Gy | Protects against gamma radiation-induced DNA damage and acts as an antioxidant or pro-oxidant product | [ |
| Naringin | 50 and 100 µM | 6 Gy | Prevents radiation-induced multiple cellular anomalies. | [ |
| Paeoniflorin | 200 μg/mL | 4 Gy | Offers protection against radiation-induced cell damage through modulation of reactive oxygen species and the mitogen-activated protein kinases in thymocytes. | [ |
| 50–200 µg/mL | 10 Gy | Protected EA.hy926 cells against radiation-induced injury through the Nrf2/HO-1 pathway. | [ | |
| Luteolin | 10 μmol/kg b.wt. | 6 Gy | Radioprotective effects through antioxidative property in mice. | [ |
| Lignans from | 500 µg/mL | 4.26 Gy | Radioprotection through immunomodulation in mammalian splenocytes. | [ |
| Hesperidin | 50–100 mg/kg b.wt. | 5 Gy | Protects against γ-radiation-induced cellular damage and oxidative stress in rats. | [ |
| α-tocopherol | 360 mg/kg b.wt. | 15 Gy | Radioprotective effect of Vitamin E in Parotid Glands in rats. | [ |
| Catechines | 100 μM | 3 Gy | Protects pBR322 DNA under acellular conditions and normal splenocytes under cellular conditions, against γ-radiation-induced damage. | [ |
| Orientin | 17.5 μM | 4 Gy | Promotes stem cell survival, exogenous spleen colony formation (CFU-S). | [ |
| Silymarin | 50 mg/kg | 3 Gy | Protects experimental animals from radiation-induced hepatotoxicity. | [ |
| Zingerone | 10 μg/mL | 2 Gy | Prevents radiation-induced genetic damage and apoptosis in human lymphocytes. | [ |
| Rutin | 10 mg/kg b.wt. | 3 Gy | Mitigates radiation-induced mortality and cytogenetic damage, which attributes to scavenging of radiation-induced free radicals. | [ |
| Lycopene | 5 mg/kg b.wt. | 6 Gy | Protects the small intestine against radiation-induced damage. | [ |
| Glycyrrhizic acid | 4 mM | 1.25 Gy | Offers protection against γ-radiation-induced DNA damage to plasmid pBR322 | [ |
| Naringin | 7.5 mg/kg b.wt. | 1–5 Gy | Protects mouse bone marrow cells against radiation-induced chromosomal aberrations and lipid peroxidation. | [ |
| Quercetin | 2–50 μM | 30 Gy | Protects against radiation- and storage-induced oxidative damage to RBCs. | [ |
| Morin | 25 μM | 10 Gy | Protects against oxidative stress induced by radiation via reduction of ROS and attenuation of the SEK1-JNK-AP-1 pathway. | [ |
| Dehydrozingerone | 100 mg/kg b.wt. | 10 Gy | Exhibits radioprotective activity in whole body gamma irradiated Swiss albino mice through free radical scavenging. The DMF value was found to be 1.09. | [ |
| Famotidine | 200 µg/mL | 4–12 Gy | Suppresses radiation-induced apoptosis with various doses of gamma-irradiation via radical scavenging and intracellular antioxidation mechanism. | [ |
| Pilocarpine | 4 mg/kg b.wt. | 15 Gy | Amelioration of long term radiation-induced hyposalivation using prophylactic pilocarpine treatment | [ |
| Podophyllotoxin | 10 nM | 10 Gy | Derivatives are used in combination with IR therapy and suggest that the EGFR–p38/ERK–STAT3/CREB-1–EMT pathway might be a useful target for suppressing metastasis. | [ |
| Hypericin | 5 µM | 8 Gy | Enhancement of radiosensitivity in human malignant glioma cells. | [ |
| Epigallocatechin-galate | 25 mg/kg b.wt. | 22 Gy | Inhibits irradiation-induced pulmonary fibrosis. | [ |
| Resveratrol | 1 mg/mL | 70 kGy | Reduces toxicity and plays a potent role in the treatment of inflammatory disease. | [ |
| Curcumin | 100 μM | 10 Gy | Acts as radiosensitizer through prooxidant mechanisms in cancer cells. | [ |
| Gossypol | 2 μM | 6 Gy | Radiosensitization of tumour cell lines by depressig double-strand break repair mechanism. | [ |
| Betulinic acid | 20 μM | 2 Gy | Induces cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions. | [ |
| Plumbagin | 750 nM | 2 Gy | Radiosensitizing effects in cervical cancer cells through modulation of apoptotic pathway. | [ |
| Withaferin A | 4 μM | 10 Gy | Enhances radiation-induced apoptosis in Caki cells through induction of reactive oxygen species, Bcl-2 downregulation and Akt inhibition. | [ |
| Ellagic acid | 100 μmol/L | 6 Gy | Enhances radiation-induced oxidative stress and subsequent cytotoxicity in tumor cells. | [ |
| Caffeic acid | 10μmol/kgb.wt. | 7 Gy | Exhibits curable effects on gamma irradiation-induced cardiac-oxidative impairment in rats. | [ |
| Genistein | 20 μM | 5 Gy | Acts as a prooxidant in HL-60 cells, increases ionizing radiation-induced cell cycle arrest and sensitivity to apoptotic cell death in human promyeloid leukemia HL-60 cells. | [ |
| Myricetin | 25 µM | 2 Gy | Enhances radiosensitivity of lung cancer A549 and H1299 cells. | [ |
| Biochanin A | 1–100 µM | 2 Gy | Enhances radiotoxicity in colon tumor cells. | [ |
| Capsaicin | 1–10 µM | 1–8 Gy | Increases radiation effects in prostate cancer. | [ |
| Piperine | 40 μM | 15 Gy | Enhances radiosensitivity of tumor cells through oxidative mechanism. | [ |
| Lupeol | 30 μmol/L | 4 Gy | Enhances radiosensitivity of human hepatocellular carcinoma cell line SMMC-7721 | [ |
| Oleanolic acid | 35 µg/mL | 250 Gy/min | Radiosensitizes tumor cells through the inhibition of GSH synthesis | [ |